Abstract
The aim of this study was to investigate thiotepa (TT) and fludarabine (Fluda) as a preparative regimen for allogeneic peripheral stem cell transplant in patients not eligible for a standard myeloablative regimen due to comorbidities and/or poor performance status. TT was given at a dose of 10 mg/kg over 2 days and Fluda at 125 mg/m2 over 5 days. In all, 21 patients (14 male, seven female; 10 acute leukaemia, eight myelodysplastic syndrome, two non-Hodgkin's lymphoma, one Hodgkin's disease) were treated. The median age was 51 years (range 30-55 years). All patients achieved full donor-type chimaerism. Adverse events included mild nausea and vomiting in two patients and a slight increase of serum amylase in three. A total of 13 patients received RBC transfusions (median 6U, range 1-23), and all received platelets (median 4U, range 1-27). Four patients died of nonrelapse causes and five of relapse. The 1-year probabilities of transplant-related mortality and relapse were 19 and 29%, respectively. In total, 12 patients remain in complete remission (median follow-up: 786 days). The 3-year overall survival probability was 58%. We conclude that this regimen is feasible and well tolerated.
| Original language | English |
|---|---|
| Pages (from-to) | 1039-1045 |
| Number of pages | 7 |
| Journal | Bone Marrow Transplantation |
| Volume | 34 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2004 |
Fingerprint
Keywords
- Allogeneic stem cell transplantation
- Fludarabine
- Reduced-intensity conditioning regimen
- Thiotepa
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. / Alessandrino, E. P.; Bernasconi, P.; Colombo, A. A.; Caldera, D.; Malcovati, L.; Troletti, D.; Vanelli, L.; Verettoni, M.; Montanari, F.; Lazzarino, M.
In: Bone Marrow Transplantation, Vol. 34, No. 12, 12.2004, p. 1039-1045.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies
AU - Alessandrino, E. P.
AU - Bernasconi, P.
AU - Colombo, A. A.
AU - Caldera, D.
AU - Malcovati, L.
AU - Troletti, D.
AU - Vanelli, L.
AU - Verettoni, M.
AU - Montanari, F.
AU - Lazzarino, M.
PY - 2004/12
Y1 - 2004/12
N2 - The aim of this study was to investigate thiotepa (TT) and fludarabine (Fluda) as a preparative regimen for allogeneic peripheral stem cell transplant in patients not eligible for a standard myeloablative regimen due to comorbidities and/or poor performance status. TT was given at a dose of 10 mg/kg over 2 days and Fluda at 125 mg/m2 over 5 days. In all, 21 patients (14 male, seven female; 10 acute leukaemia, eight myelodysplastic syndrome, two non-Hodgkin's lymphoma, one Hodgkin's disease) were treated. The median age was 51 years (range 30-55 years). All patients achieved full donor-type chimaerism. Adverse events included mild nausea and vomiting in two patients and a slight increase of serum amylase in three. A total of 13 patients received RBC transfusions (median 6U, range 1-23), and all received platelets (median 4U, range 1-27). Four patients died of nonrelapse causes and five of relapse. The 1-year probabilities of transplant-related mortality and relapse were 19 and 29%, respectively. In total, 12 patients remain in complete remission (median follow-up: 786 days). The 3-year overall survival probability was 58%. We conclude that this regimen is feasible and well tolerated.
AB - The aim of this study was to investigate thiotepa (TT) and fludarabine (Fluda) as a preparative regimen for allogeneic peripheral stem cell transplant in patients not eligible for a standard myeloablative regimen due to comorbidities and/or poor performance status. TT was given at a dose of 10 mg/kg over 2 days and Fluda at 125 mg/m2 over 5 days. In all, 21 patients (14 male, seven female; 10 acute leukaemia, eight myelodysplastic syndrome, two non-Hodgkin's lymphoma, one Hodgkin's disease) were treated. The median age was 51 years (range 30-55 years). All patients achieved full donor-type chimaerism. Adverse events included mild nausea and vomiting in two patients and a slight increase of serum amylase in three. A total of 13 patients received RBC transfusions (median 6U, range 1-23), and all received platelets (median 4U, range 1-27). Four patients died of nonrelapse causes and five of relapse. The 1-year probabilities of transplant-related mortality and relapse were 19 and 29%, respectively. In total, 12 patients remain in complete remission (median follow-up: 786 days). The 3-year overall survival probability was 58%. We conclude that this regimen is feasible and well tolerated.
KW - Allogeneic stem cell transplantation
KW - Fludarabine
KW - Reduced-intensity conditioning regimen
KW - Thiotepa
UR - http://www.scopus.com/inward/record.url?scp=19944386623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944386623&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1704717
DO - 10.1038/sj.bmt.1704717
M3 - Article
C2 - 15516936
AN - SCOPUS:19944386623
VL - 34
SP - 1039
EP - 1045
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 12
ER -